BRCA1 and ovarian carcinoma: This approach has so far demonstrated the most significant efficacy in breast and ovarian cancers with known BRCA1/2 mutations, with advanced FDA (Food and Drug Administration) approval granted for the treatment of BRCA-mutant ovarian and prostate cancers.